SZLSF (StageZero Life Sciences) Long-Term Capital Lease Obligation : $0.13 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences Long-Term Capital Lease Obligation?

StageZero Life Sciences's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.13 Mil.

StageZero Life Sciences's quarterly Long-Term Capital Lease Obligation increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.15 Mil) but then declined from Jun. 2024 ($0.15 Mil) to Sep. 2024 ($0.13 Mil).

StageZero Life Sciences's annual Long-Term Capital Lease Obligation declined from Dec. 2020 ($0.42 Mil) to Dec. 2021 ($0.19 Mil) and declined from Dec. 2021 ($0.19 Mil) to Dec. 2022 ($0.00 Mil).

StageZero Life Sciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for StageZero Life Sciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Long-Term Capital Lease Obligation Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.60

0.42

0.19

StageZero Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	0.15	0.13

StageZero Life Sciences (OTCPK:SZLSF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

StageZero Life Sciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.